Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review

Journal of Affective Disorders

Volumn 82, Issue 2, 2004, Pages 167-174

  Sareen, Jitender ^a   Kirshner, Alla ^a   Lander, Mark ^a   Kjernisted, Kevin D ^a   Eleff, Michael K ^a   Reiss, Jeffrey P ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antipsychotic; Obsessive Compulsive Disorder; Refractory

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CLOMIPRAMINE; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PLACEBO; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AKATHISIA; CLINICAL TRIAL; DISEASE EXACERBATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EXTRAPYRAMIDAL SYNDROME; HUMAN; INCREASED APPETITE; LONG TERM EXPOSURE; MEDICAL RESEARCH; MEDLINE; MORBIDITY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; PSYCINFO; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TIME SERIES ANALYSIS;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 5644257264     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2004.03.011     Document Type: Review

References (45)

1. Atmaca M., Kuloglu M., Tezcan E., Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 17:2002;115-119
2. Baker R.W., Chengappa K.N., Baird J.W., Steingard S., Christ M.A., Schooler N.R. Emergence of obsessive compulsive symptoms during treatment with clozapine. J. Clin. Psychiatry. 53:1992;439-442
3. Baker R.W., Ames D., Umbricht D.S., Chengappa K.N., Schooler N.R. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol. Bull. 32:1996;89-93
4. Bergeron R., Ravindran A.V., Chaput Y., Goldner E., Swinson R., van Ameringen M.A., Austin C., Hadrava V. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J. Clin. Psychopharmacol. 22:2002;148-154
5. Bezchlibnyk-Butler K.Z., Jeffries J.J. Clinical Handbook of Psychotropic Drugs. 2003;Hogrefe & Huber Publishers, Toronto, Canada
6. Biondi M., Fedele L., Arcangeli T., Pancheri P. Development of obsessive-compulsive symptoms during clozapine treatment in schizophrenia and its positive response to clomipramine. Psychother. Psychosom. 68:1999;111-112
7. Bogetto F., Bellino S., Vaschetto P., Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 96:2000;91-98
8. Bystritsky A., Ackerman D.L., Rosen R.M. Augmentation of SSRI response in refractory OCD using adjunctive olanzapine: a placebo controlled trial. Fifth International Obsessive Compulsive Disorder Conference, Sardinia, Italy. 2001
9. Calvocoressi L., Lewis B., Harris M., Trufan S.J., Goodman W.K., McDougle C.J., Price L.H. Family accommodation in obsessive-compulsive disorder. Am. J. Psychiatry. 152:1995;441-443
10. Cheung E.F. Obsessive-compulsive symptoms during treatment with clozapine in a patient with schizophrenia. Aust. N. Z. J. Psychiatry. 35:2001;695-696
11. Conley R.R., Kelly D.L. Management of treatment resistance in schizophrenia. Biol. Psychiatry. 50:2001;898-911
12. de Haan L., Linszen D.H., Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J. Clin. Psychiatry. 60:1999;364-365
13. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can. J. Psychiatry. 46:2001;356-358
14. Greist J.H., Jefferson J.W., Kobak K.A., Katzelnick D.J., Serlin R.C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch. Gen. Psychiatry. 52:1995;53-60
15. Hollander E., Bienstock C.A., Koran L.M., Pallanti S., Marazziti D., Rasmussen S.A., Ravizza L., Benkelfat C., Saxena S., Greenberg B.D., Sasson Y., Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J. Clin. Psychiatry. 63(Suppl. 6):2002;20-29
16. Jacobsen F.M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J. Clin. Psychiatry. 56:1995;423-429
17. Jenike M.A., Rauch S.L. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. J. Clin. Psychiatry. 55 Suppl.:1994;11-17
18. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry. 155:1998;921-928
19. Karno M., Golding J.M., Sorenson S.B., Burnam M.A. The epidemiology of obsessive-compulsive disorder in five US communities. Arch. Gen. Psychiatry. 45:1988;1094-1099
20. Kopala L., Honer W.G. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am. J. Psychiatry. 151:1994;1714-1715
21. Koran L.M., Ringold A.L., Elliott M.A. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry. 61:2000;514-517
22. LaPorta L.D. More on obsessive-compulsive symptoms and clozapine. J. Clin. Psychiatry. 55:1994;312
23. Leonard H.L., Swedo S.E., Lenane M.C., Rettew D.C., Hamburger S.D., Bartko J.J., Rapoport J.L. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch. Gen. Psychiatry. 50:1993;429-439
24. Maina G., Albert U., Ziero S., Bogetto F. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int. Clin. Psychopharmacol. 18:2003;23-28
25. McDougle C.J., Goodman W.K., Price L.H., Delgado P.L., Krystal J.H., Charney D.S., Heninger G.R. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry. 147:1990;652-654
26. McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., Price L.H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry. 51:1994;302-308
27. McDougle C.J., Barr L.C., Goodman W.K., Pelton G.H., Aronson S.C., Anand A., Price L.H. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am. J. Psychiatry. 152:1995;1812-1814
28. McDougle C.J., Epperson C.N., Pelton G.H., Wasylink S., Price L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry. 57:2000;794-801
29. Mohr N., Vythilingum B., Emsley R.A., Stein D.J. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 17:2002;37-40
30. Morrison D., Clark D., Goldfarb E., McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am. J. Psychiatry. 155:1998;855
31. Mottard J.P., de la Sablonniere J.F. Olanzapine-induced obsessive-compulsive disorder. Am. J. Psychiatry. 156:1999;799-800
32. Patel B., Tandon R. Development of obsessive-compulsive symptoms during clozapine treatment. Am. J. Psychiatry. 150:1993;836
33. Pfanner C., Marazziti D., Dell'Osso L., Presta S., Gemignani A., Milanfranchi A., Cassano G.B. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int. Clin. Psychopharmacol. 15:2000;297-301
34. Rahman M.S., Grace J.J., Pato M.T., Priest B. Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior. Am. J. Psychiatry. 155:1998;1629-1630
35. Ramasubbu R., Ravindron A., Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry. 33:2000;236-238
36. Rasmussen S.A., Eisen J.L. Epidemiology and differential diagnosis of obsessive-compulsive disorder. J. Clin. Psychiatry. 55:1994;5-14
37. Rasmussen S.A., Eisen J.L. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J. Clin. Psychiatry. 58(Suppl. 13):1997;9-13
38. Ravizza L., Barzega G., Bellino S., Bogetto F., Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol. Bull. 32:1996;677-682
39. Remington G., Adams M. Risperidone and obsessive-compulsive symptoms. J. Clin. Psychopharmacol. 14:1994;358-359
40. Sasson Y., Zohar J., Chopra M., Lustig M., Iancu I., Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J. Clin. Psychiatry. 58(Suppl. 12):1997;7-10
41. Sasson Y., Amiaz R., Nakash N. Olanzapine treatment for schizophrenia patients with refractory OCD: an open-label case series. Fifth International Obsessive Compulsive Disorder Conference; Sardinia, Italy. 2001
42. Saxena S., Wang D., Bystritsky A., Baxter L.R. Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry. 57:1996;303-306
43. Stein D.J., Bouwer C., Hawkridge S., Emsley R.A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J. Clin. Psychiatry. 58:1997;119-122
44. Sussman N. The implications of weight changes with antipsychotic treatment. J. Clin. Psychopharmacol. 23:2003;S21-S26
45. Tibbo P., Warneke L. Obsessive-Compulsive disorder in Schizophrenia: epidemiologic and biologic overlap. J. Psychiatry Neurosci. 24:1999;15-24